DOCSLIB.ORG

Tribbles Homolog 2 (Trib2), a Pseudo Serine/Threonine Kinase In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tribbles Homolog 2 (Trib2), a Pseudo Serine/Threonine Kinase In Fang et al. Cell Commun Signal (2021) 19:41 https://doi.org/10.1186/s12964-021-00725-y REVIEW Open Access Tribbles homolog 2 (Trib2), a pseudo serine/ threonine kinase in tumorigenesis and stem cell fate decisions Yu Fang1,2*, Angelina Olegovna Zekiy3, Farhoodeh Ghaedrahmati4, Anton Timoshin5, Maryam Farzaneh6 , Amir Anbiyaiee7 and Seyed Esmaeil Khoshnam8 Abstract The family of Tribbles proteins play many critical nonenzymatic roles and regulate a wide range of key signaling pathways. Tribbles homolog 2 (Trib2) is a pseudo serine/threonine kinase that functions as a scafold or adaptor in various physiological and pathological processes. Trib2 can interact with E3 ubiquitin ligases and control protein sta- bility of downstream efectors. This protein is induced by mitogens and enhances the propagation of several cancer cells, including myeloid leukemia, liver, lung, skin, bone, brain, and pancreatic. Thus, Trib2 can be a predictive and valuable biomarker for the diagnosis and treatment of cancer. Recent studies have illustrated that Trib2 plays a major role in cell fate determination of stem cells. Stem cells have the capacity to self-renew and diferentiate into specifc cell types. Stem cells are important sources for cell-based regenerative medicine and drug screening. Trib2 has been found to increase the self-renewal ability of embryonic stem cells, the reprogramming efciency of somatic cells, and chondrogenesis. In this review, we will focus on the recent advances of Trib2 function in tumorigenesis and stem cell fate decisions. Keywords: Pluripotent stem cells, Tribbles homolog 2, Tumorigenesis, Pluripotency, Reprogramming, Stem cell fate, Regenerative medicine Background E3 ubiquitin ligases and control protein stability of down- Tribbles homolog 2 (Trib2) is a pseudo serine/threo- stream efectors [7]. Trib2 as a mitosis blocker regulates nine kinase and a member of the Tribbles family that various cellular processes, including germ cell devel- functions as a scafold or adaptor in signaling pathways opment, apoptosis, proliferation, lineage specifcation, in a number of physiological and pathological processes reproduction, infammation, innate immunity, and drug [1–3]. Te family of Tribbles proteins play many criti- resistance [8–11]. It is known that Trib2 has diverse roles cal nonenzymatic roles and regulate a wide range of key in neurological disorders, metabolic diseases, autoim- signaling pathways such as mitogen-activated protein mune and infammatory diseases, arthritis, and a number kinase (MAPKs), nuclear factor-κB (NF-kB), PI3K/AKT, of cancers (chronic myeloid leukemia, liver, melanoma, and activating transcription factor 4 (ATF4) in healthy and ovarian) [3, 12, 13]. In human cancer, Trib2 as a and pathological processes [4–6]. Trib2 can interact with cancer-associated pseudokinase and novel oncogene can enhance cell proliferation and stimulate cell cycle arrest *Correspondence: [email protected] [14]. Trib2, recently identifed as the cause of cancer 1 Anyang Center for Chemical and Pharmaceutical Engineering, College drug resistance [15, 16]. Tere is substantial evidence of Chemistry and Chemical Engineering, Anyang Normal University, Anyang 455000, Henan, People’s Republic of China that Trib2 can be a predictive and valuable biomarker for Full list of author information is available at the end of the article cancer diagnosis and treatment [6, 17]. Recent studies © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Fang et al. Cell Commun Signal (2021) 19:41 Page 2 of 8 have illustrated that Trib2 plays a major role in cell fate Little information is known about the role of Trib2 in determination of stem cells [2]. Stem cells are undifer- mammals [9, 27]. Trib2 has a low afnity for ATP and entiated cells that have the capacity to self-renew and dif- further structural studies are required for the ATP-bind- ferentiate into specifc cell types [18, 19]. Stem cells are ing status of this protein [6, 14]. Trib2 via a ubiquitin- classifed into pluripotent (embryonic stem cells (ESCs) and proteasome-dependent pathway regulates the cell and induced pluripotent stem cells (iPSCs)), multipo- cycle in human cells [31, 36]. It should be noted that both tent (mesenchymal stem cells (MSCs) and hematopoi- the Trib2 kinase domain and COP1 binding are essential etic stem cells (HSCs)), and unipotent stem cells [20–22]. for the ability of Trib2 to degrade C/EBPα [37]. Trib2 has Human PSCs and MSCs are important sources for cell- been reported to be a pro-apoptotic molecule that stimu- based regenerative medicine, tissue engineering, and lates apoptosis via a caspase-dependent mechanism [38]. drug screening [23–25]. Trib2 has been found to increase Trib2 with the expression of pro- and anti-infammatory the self-renewal ability of ESCs, the reprogramming ef- immune modulators appears to be essential for innate ciency of somatic cells, and chondrogenesis [2]. In this immunity [39]. Trib2 as an important regulator of nor- review, we will focus on the recent advances of Trib2 mal hematopoiesis can regulate the diferentiation poten- function in tumorigenesis and stem cell fate decisions. tial of intrathymic precursors and the checkpoints of thymopoiesis [11]. Te function of monocytes and mac- Structure and function of Trib2 rophages can be modulated by Trib2 [40, 41]. Trib2 has Tribbles (Trib) is a critical regulator of embryonic devel- been shown to regulate the development of T-cell and opment that for the frst time identifed in Drosophila erythroid cells [42, 43]. Tis protein as an anti-infamma- [26]. In the human genome, the Trib proteins have three tory factor negatively regulates NF-κB (p100) activity in homologs, including TRIB1, TRIB2, and TRIB3, with the TLR5 pathway [9, 44]. During follicular development, a single kinase-like and highly conserved domain that Trib2 increases the activity of the MAPK/ERK pathway encodes pseudo-kinase proteins [9]. Trib2 contains an and regulates granulosa cells (GCs) proliferation and N-terminal domain (PEST), a C-terminal E3 ligase-bind- function [45]. ing domain, and a pseudokinase domain with a Ser/Tr protein kinase-like domain (without a canonical ‘DFG’ Diferent roles of Trib2 in tumorigenesis (metal-binding) motif) [1, 26]. Trib2 is a cancer-associated pseudokinase that can be Te C-terminal domain has the HPW [F/L] motif (tar- induced by mitogens and enhances the propagation of gets MAPKK/MEK family members) and the conserved several cancer cells, including myeloid leukemia, liver, DQXVP [D/E] peptide motif (binds to COP1 E3 ubiqui- lung, skin, bone, brain, and pancreatic [10, 46] (Table 1). tin ligases) [27]. Te pseudokinase domain has a unique In normal murine hematopoiesis, TRIB2 function is cysteine-rich C-helix that binds with E3 ubiquitin ligases necessary for the thymopoietic reaction to oncogenic [28] (Fig. 1). stress [47]. In hematological malignancies, TRIB2 as a TRIB proteins through E3 ligase-dependent ubiquitina- target gene of MEIS1, E2F1, and NOTCH1 participates in tion (pseudokinase mechanism) and scafolding (with the acute myeloid leukemia (AML) and T cell acute lympho- MAPK and AKT pathway) have the potential to control blastic leukemia (T-ALL) [42, 48, 49]. In human AML, cell proliferation, apoptosis, survival, and diferentiation Trib2 has been reported to be a negative regulator of C/ [27]. Te family of Tribbles proteins can regulate a wide EBPα expression and enhances AML progression [50]. In range of signaling pathways such as mitogen-activated patient-derived human AML cells, Trib2 enhances the protein kinase (MAPKs), nuclear factor-κB (NF-kB), pro- expression of anti-apoptotic B-cell lymphoma 2 (BCL2) tein kinase B (PKB or AKT), and activating transcription [51]. In chronic myelogenous leukemia (CML), Trib2 factor 4 (ATF4) [4–6]. In the Toll-like receptor (TLR) through the ERK pathway increases cell proliferation and signaling pathway, Trib1 negatively controls the expres- drug resistance [12]. Smad ubiquitination regulatory fac- sion of CCAAT/enhancer-binding protein β (C/EBPβ) tor 1 (Smurf1) is a HECT-type E3 ubiquitin ligase that [29]. Trib1 and Trib2 are able to recruit the E3 ligase and acts as a tumor enhancer or suppressor in various bio- induce C/EBPα and C/EBPβ degradation [30, 31]. Tere- logical processes [52]. Trib2 by regulating the degrada- fore, TRIBs through the degradation of C/EBP transcrip- tion of E3 ubiquitin ligase βTrCP, COP1, and Smurf1 can tion factors promote oncogenesis [6]. Trib3 has been inhibit the Wnt pathway and reduce cell propagation in shown to regulate serine-threonine kinase AKT (PKB), myeloid leukemia [53]. In response to stress, TRIB2 as a p65/rel A, and activating ATF4 [32–34]. Trib1 and Trib3 tumor suppressor stimulates activation of p38 stress sign- in response to various pro-infammatory stimuli trigger aling in myeloid leukemia [54]. Tus, Trib2 may decrease the MAP kinase pathway and regulate the activator pro- the ability of leukaemia cells to propagate [54]. In T-ALL, tein 1 (AP-1)-related pathway [35].
Load more

Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • TRIB2 Functions As Novel Oncogene in Colorectal Cancer by Blocking
    Hou et al. Molecular Cancer (2018) 17:172 https://doi.org/10.1186/s12943-018-0922-x RESEARCH Open Access TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling Zhenlin Hou1, Kaixuan Guo1, Xuling Sun1, Fuqing Hu1, Qianzhi Chen1, Xuelai Luo1, Guihua Wang1, Junbo Hu1 and Li Sun2* Abstract Background: Cellular senescence is a state of irreversible cell growth arrest and senescence cells permanently lose proliferation potential. Induction of cellular senescence might be a novel therapy for cancer cells. TRIB2 has been reported to participate in regulating proliferation and drug resistance of various cancer cells. However, the role of TRIB2 in cellular senescence of colorectal cancer (CRC) and its molecular mechanism remains unclear. Methods: The expression of TRIB2 in colorectal cancer tissues and adjacent tissues was detected by immunohistochemistry and RT-PCR. The growth, cell cycle distribution and cellular senescence of colorectal cancer cells were evaluated by Cell Counting Kit-8 (CCK8) assay, flow cytometry detection and senescence- associated β-galactosidase staining, respectively. Western blot, RT-PCR and luciferase assay were performed to determine how TRIB2 regulates p21. Immunoprecipitation (IP) and chromatin-immunoprecipitation (ChIP) were used to investigate the molecular mechanisms. Results: We found that TRIB2 expression was elevated in CRC tissues compared to normal adjacent tissues and high TRIB2 expression indicated poor prognosis of CRC patients. Functionally, depletion of TRIB2 inhibited cancer cells proliferation, induced cell cycle arrest and promoted cellular senescence, whereas overexpression of TRIB2 accelerated cell growth, cell cycle progression and blocked cellular senescence. Further studies showed that TRIB2 physically interacted with AP4 and inhibited p21 expression through enhancing transcription activities of AP4.
    [Show full text]
  • Characterization of TRIB2-Mediated Resistance to Pharmacological Inhibition of MEK
    VANESSA MENDES HENRIQUES Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK Oncobiology Master Thesis Faro, 2017 VANESSA MENDES HENRIQUES Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK Supervisors: Dr. Wolfgang Link Dr. Bibiana Ferreira Oncobiology Master Thesis Faro, 2017 Título: “Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK” Declaração de autoria do trabalho Declaro ser a autora deste trabalho, que é original e inédito. Autores e trabalhos consultados estão devidamente citados no texto e constam da listagem de referências incluída. Copyright Vanessa Mendes Henriques _____________________________ A Universidade do Algarve tem o direito, perpétuo e sem limites geográficos, de arquivar e publicitar este trabalho através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, de o divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objetivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. i Acknowledgements First, I would like to thank the greatest opportunity given by professor doctor Wolfgang Link to accepting me into his team, contributing to my scientific and personal progress. Thank You for all Your knowledge and help across the year. A special thanks to Bibiana Ferreira who stayed by me all year and trained me. Thank You for all you taught me, thank you for all your patience and time and all the support. Thank you for all the great times that You provided me. It was an amazing experience to learn and work with You, which made me grow as a scientist and also as a person.
    [Show full text]
  • TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance
    Author Manuscript Published OnlineFirst on June 24, 2019; DOI: 10.1158/1078-0432.CCR-19-0510 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance Jian Lin1, 3, Wu Zhang1, 3, *, Li-Ting Niu1, Yong-Mei Zhu1, Xiang-Qin Weng1, Yan Sheng1, Jiang Zhu1 and Jie Xu1, 2, * 1State Key Laboratory for Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine and School of Life Sciences and Biotechnology, Shanghai Jiao-Tong University, 197 Ruijin Er Road, Shanghai 200025, China. 2Translational Medicine Ward, Department of Hematology, Rui-Jin Hospital, Shanghai 200025, China. 3These authors contributed equally to this work. *Correspondence: Jie Xu, State Key Laboratory for Medical Genomics and Shanghai Institute of Hematology Rui-Jin Hospital, affiliated to Shanghai Jiao-Tong University School of Medicine, Shanghai, 200025, China. E-mail: [email protected]; and Wu Zhang, State Key Laboratory for Medical Genomics and Shanghai Institute of Hematology Rui-Jin Hospital, affiliated to Shanghai Jiao-Tong University School of Medicine, Shanghai, 200025, China. E-mail: [email protected]; Running title: TRIB3 stabilizes TWIST1 to promote APL progression Key words: Acute promyelocytic leukemia; TWIST1; TRIB3; Early death; ATRA-resistance Conflict of interest statement: The authors declare no potential conflicts of interest. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 24, 2019; DOI: 10.1158/1078-0432.CCR-19-0510 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • The New Antitumor Drug ABTL0812 Inhibits the Akt/Mtorc1 Axis By
    Published OnlineFirst December 15, 2015; DOI: 10.1158/1078-0432.CCR-15-1808 Cancer Therapy: Preclinical Clinical Cancer Research The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase Tatiana Erazo1, Mar Lorente2,3, Anna Lopez-Plana 4, Pau Munoz-Guardiola~ 1,5, Patricia Fernandez-Nogueira 4, Jose A. García-Martínez5, Paloma Bragado4, Gemma Fuster4, María Salazar2, Jordi Espadaler5, Javier Hernandez-Losa 6, Jose Ramon Bayascas7, Marc Cortal5, Laura Vidal8, Pedro Gascon 4,8, Mariana Gomez-Ferreria 5, Jose Alfon 5, Guillermo Velasco2,3, Carles Domenech 5, and Jose M. Lizcano1 Abstract Purpose: ABTL0812 is a novel first-in-class, small molecule tion of Tribbles-3 pseudokinase (TRIB3) gene expression. Upre- which showed antiproliferative effect on tumor cells in pheno- gulated TRIB3 binds cellular Akt, preventing its activation by typic assays. Here we describe the mechanism of action of this upstream kinases, resulting in Akt inhibition and suppression of antitumor drug, which is currently in clinical development. the Akt/mTORC1 axis. Pharmacologic inhibition of PPARa/g or Experimental Design: We investigated the effect of ABTL0812 TRIB3 silencing prevented ABTL0812-induced cell death. on cancer cell death, proliferation, and modulation of intracel- ABTL0812 treatment induced Akt inhibition in cancer cells, tumor lular signaling pathways, using human lung (A549) and pancre- xenografts, and peripheral blood mononuclear cells from patients atic (MiaPaCa-2) cancer cells and tumor xenografts. To identify enrolled in phase I/Ib first-in-human clinical trial. cellular targets, we performed in silico high-throughput screening Conclusions: ABTL0812 has a unique and novel mechanism of comparing ABTL0812 chemical structure against ChEMBL15 action, that defines a new and drugable cellular route that links database.
    [Show full text]
  • Integrated Analysis of Gene Expression Changes Associated
    Miao et al. Lipids in Health and Disease (2019) 18:92 https://doi.org/10.1186/s12944-019-1032-5 RESEARCH Open Access Integrated analysis of gene expression changes associated with coronary artery disease Liu Miao1 , Rui-Xing Yin1,2,3* , Feng Huang1,2,3, Shuo Yang1, Wu-Xian Chen1 and Jin-Zhen Wu1 Abstract Background: This study investigated the pathways and genes involved in coronary artery disease (CAD) and the associated mechanisms. Methods: Two array data sets of GSE19339 and GSE56885 were downloaded. The limma package was used to analyze the differentially expressed genes (DEGs) in normal and CAD specimens. Examination of DEGs through Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and Gene Ontology annotation was achieved by Database for Annotation, Visualization and Integrated Discovery (DAVID). The Cytoscape software facilitated the establishment of the protein-protein interaction (PPI) network and Molecular Complex Detection (MCODE) was performed for the significant modules. Results: We identified 413 DEGs (291 up-regulated and 122 down-regulated). Approximately 256 biological processes, only 1 cellular component, and 21 molecular functions were identified by GO analysis and 10 pathways were enriched by KEGG. Moreover, 264 protein pairs and 64 nodes were visualized by the PPI network. After the MCODE analysis, the top 4 high degree genes, including interleukin 1 beta (IL1B, degree = 29), intercellular adhesion molecule 1 (ICAM1, degree = 25), Jun proto-oncogene (JUN, degree = 23) and C-C motif chemokine ligand 2 (CCL2, degree = 20) had been identified to validate in RT-PCR and Cox proportional hazards regression between CAD and normals. Conclusions: The relative expression of IL1B, ICAM1 and CCL2 was higher in CAD than in normal controls (P <0.05–0.
    [Show full text]
  • Chemical Agent and Antibodies B-Raf Inhibitor RAF265
    Supplemental Materials and Methods: Chemical agent and antibodies B-Raf inhibitor RAF265 [5-(2-(5-(trifluromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-trifluoromethyl)phenyl-1-methyl-1H-benzp{D, }imidazol-2- amine] was kindly provided by Novartis Pharma AG and dissolved in solvent ethanol:propylene glycol:2.5% tween-80 (percentage 6:23:71) for oral delivery to mice by gavage. Antibodies to phospho-ERK1/2 Thr202/Tyr204(4370), phosphoMEK1/2(2338 and 9121)), phospho-cyclin D1(3300), cyclin D1 (2978), PLK1 (4513) BIM (2933), BAX (2772), BCL2 (2876) were from Cell Signaling Technology. Additional antibodies for phospho-ERK1,2 detection for western blot were from Promega (V803A), and Santa Cruz (E-Y, SC7383). Total ERK antibody for western blot analysis was K-23 from Santa Cruz (SC-94). Ki67 antibody (ab833) was from ABCAM, Mcl1 antibody (559027) was from BD Biosciences, Factor VIII antibody was from Dako (A082), CD31 antibody was from Dianova, (DIA310), and Cot antibody was from Santa Cruz Biotechnology (sc-373677). For the cyclin D1 second antibody staining was with an Alexa Fluor 568 donkey anti-rabbit IgG (Invitrogen, A10042) (1:200 dilution). The pMEK1 fluorescence was developed using the Alexa Fluor 488 chicken anti-rabbit IgG second antibody (1:200 dilution).TUNEL staining kits were from Promega (G2350). Mouse Implant Studies: Biopsy tissues were delivered to research laboratory in ice-cold Dulbecco's Modified Eagle Medium (DMEM) buffer solution. As the tissue mass available from each biopsy was limited, we first passaged the biopsy tissue in Balb/c nu/Foxn1 athymic nude mice (6-8 weeks of age and weighing 22-25g, purchased from Harlan Sprague Dawley, USA) to increase the volume of tumor for further implantation.
    [Show full text]
  • Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis
    cancers Article Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis Parastoo Shahrouzi 1, Ianire Astobiza 1,2, Ana R. Cortazar 1,2, Verónica Torrano 1,2,3, Alice Macchia 1 , Juana M. Flores 4, Chiara Niespolo 5, Isabel Mendizabal 1 , Ruben Caloto 2,6, Amaia Ercilla 1,2 , Laura Camacho 1,3, Leire Arreal 1, Maider Bizkarguenaga 1 , Maria L. Martinez-Chantar 1,7, Xose R. Bustelo 2,6 , Edurne Berra 1,2, Endre Kiss-Toth 5 , Guillermo Velasco 8,9 , Amaia Zabala-Letona 1,2 and Arkaitz Carracedo 1,2,3,10,* 1 Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, Spain; [email protected] (P.S.); [email protected] (I.A.); [email protected] (A.R.C.); [email protected] (V.T.); [email protected] (A.M.); [email protected] (I.M.); [email protected] (A.E.); [email protected] (L.C.); [email protected] (L.A.); [email protected] (M.B.); [email protected] (M.L.M.-C.); [email protected] (E.B.); [email protected] (A.Z.-L.) 2 CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), 28029 Madrid, Spain; [email protected] (R.C.); [email protected] (X.R.B.) 3 Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P.O. Box 644, E-48080 Bilbao, Spain 4 Medicine and Surgery Department, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain; jfl[email protected] 5 Department
    [Show full text]
  • Microarray Gene Expression Analysis in Ovine Ductus Arteriosus During Fetal Development and Birth Transition
    nature publishing group Articles Basic Science Investigation Microarray gene expression analysis in ovine ductus arteriosus during fetal development and birth transition Ravi Goyal1, Dipali Goyal1, Lawrence D. Longo1 and Ronald I. Clyman2 BACKGROUND: Patent ductus arteriosus (PDA) in the new- (PDA) persists after birth, the blood shunts from the high- born is the most common congenital heart anomaly and is pressure aorta to the low-pressure pulmonary artery (left to significantly more common in preterm infants. Contemporary right shunt). This can lead to pulmonary hyperemia and edema pharmacological treatment is effective in only 70–80% of the and decreases renal, mesenteric, and cerebral perfusion result- cases. Moreover, indomethacin or ibuprofen, which are used ing in pulmonary engorgement with an increase in pulmonary to close a PDA may be accompanied by serious side effects in vascular resistance and congestive cardiac failure. In those premature infants. To explore the novel molecular pathways, cases in which the pulmonary vascular resistance exceeds which may be involved in the maturation and closure of the the systemic vascular resistance, the blood shunts from right ductus arteriosus (DA), we used fetal and neonatal sheep to test to left. The main therapeutic option for a PDA is to treat the the hypothesis that maturational development of DA is associ- neonate with indomethacin or ibuprofen to inhibit the enzyme ated with significant alterations in specific mRNA expression. cyclooxygenase and thus inhibit prostaglandin synthesis. This METHODS: We conducted oligonucleotide microarray exper- is successful in about 70–80% of infants. Its use, however, may iments on the isolated mRNA from DA and ascending aorta lead to undesirable side effects such as gastrointestinal bleed- from three study groups (premature fetus—97 ± 0 d, near-term ing, perforation, and/or necrotizing enterocolitis.
    [Show full text]
  • University of Dundee PDK1-SGK1 Signaling Sustains AKT
    University of Dundee PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3K inhibition Castel, Pau; Ellis, Haley; Bago, Ruzica; Toska, Eneda; Razavi, Pedram; Carmona, F. Javier Published in: Cancer Cell DOI: 10.1016/j.ccell.2016.06.004 Publication date: 2016 Licence: CC BY-NC-ND Document Version Peer reviewed version Link to publication in Discovery Research Portal Citation for published version (APA): Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F. J., kannan, S., Verma, C. S., Dickler, M., Chandarlapaty, S., Brogi, E., Alessi, D., Baselga, J., & Scaltriti, M. (2016). PDK1-SGK1 signaling sustains AKT- independent mTORC1 activation and confers resistance to PI3K inhibition. Cancer Cell, 30(2), 229-242. https://doi.org/10.1016/j.ccell.2016.06.004 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 05. Oct.
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • TRIB2 Confers Resistance to Anti-Cancer Therapy by Activating the Serine/Threonine Protein Kinase AKT
    ARTICLE Received 23 Nov 2015 | Accepted 23 Jan 2017 | Published 9 Mar 2017 DOI: 10.1038/ncomms14687 OPEN TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT Richard Hill1,2,3, Patricia A. Madureira2, Bibiana Ferreira2, Ineˆs Baptista2, Susana Machado2, Laura Colac¸o2, Marta dos Santos2, Ningshu Liu4, Ana Dopazo5, Selma Ugurel6, Angyal Adrienn7, Endre Kiss-Toth7, Murat Isbilen8, Ali O. Gure8 & Wolfgang Link1,2,9 Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. Here we report that tribbles homologue 2 (TRIB2) ablates forkhead box O activation and disrupts the p53/MDM2 regulatory axis, conferring resistance to various chemotherapeutics. TRIB2 suppression is exerted via direct interaction with AKT a key signalling protein in cell proliferation, survival and metabolism pathways. Ectopic or intrinsic high expression of TRIB2 induces drug resistance by promoting phospho- AKT (at Ser473) via its COP1 domain. TRIB2 expression is significantly increased in tumour tissues from patients correlating with an increased phosphorylation of AKT, FOXO3a, MDM2 and an impaired therapeutic response. This culminates in an extremely poor clinical outcome. Our study reveals a novel regulatory mechanism underlying drug resistance and suggests that TRIB2 functions as a regulatory component of the PI3K network, activating AKT in cancer cells. 1 Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro 8005-139, Portugal. 2 Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro 8005-139, Portugal.
    [Show full text]